March 22nd 2023
FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.
February 24th 2023
Ripretinib Shows Better Efficacy Than Sunitinib in Imatinib-Pretreated Patients With KIT-Mutated GISTJanuary 5th 2023
INTRIGUE study results show that patients with gastrointestinal stromal tumor who harbor certain KIT mutations have significantly improved responses and survival with ripretinib treatment.
20 Years of Trials, Hope and Progress for Patients with Pancreatic AdenocarcinomaDecember 21st 2022
In a comprehensive review of the last 20 years of advancements and challenges in the pancreatic adenocarcinoma landscape, Dr. Tomsilav Dragovich highlights how treatment has evolved for this patient population.
Zolbetuximab Combo Meets Efficacy End Points in CLDN18.2+, HER2- Gastric/GEJ CancersDecember 19th 2022
The GLOW trial of zolbetuximab plus capecitabine and oxaliplatin showed statistically significant progression-free and overall survival rates in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah Explores Treatment Options for Patients With Advanced HER2+ Gastric CancerDecember 15th 2022
During a live event, Manish A. Shah, MD, discussed the case of a 65-year-old man presented with new onset fatigue, upper abdominal pain that worsened with eating, and unintentional weight loss.
FDA Grants FTD to Pelareorep Plus Atezolizumab and Chemotherapy for Advanced PDACDecember 2nd 2022
The FDA has granted a fast track designation to the combination of pelareorep and atezolizumab with gemcitabine and nab-paclitaxel for advanced or metastatic pancreatic ductal adenocarcinoma after promising results were presented from the GOBLET study at the SITC Annual Meeting.
Trifluridine-Tipiracil, Bevacizumab Continue to Show Survival Benefits in mCRCDecember 1st 2022
Real-world research show the tolerability and effectiveness of trifluridine and tipiracil combined with bevacizumab for the treatment of patients with refractory metastatic colorectal cancer.
Earlier Use of Immunotherapy Combinations Explored in Esophageal CancerNovember 29th 2022
In an interview , Ali Zaidi, MD, discussed how the treatment landscape for patients with esophageal cancer has evolved over previous years and what research aims to look at in the near future.
Pembrolizumab Combo Prolongs Survival in HER2–, Locally Advanced Unresectable or Metastatic Gastric/GEJ CancersNovember 22nd 2022
Results from the phase 3 KEYNOTE-859 study show extended overall and progression-free survival in patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma treated with pembrolizumab and chemotherapy.
Zolbetuximab Regimen Prolongs Survival in CLDN18.2+, HER2- Locally Advanced Unresectable, Metastatic Gastric/GEJ CancersNovember 17th 2022
Initial results from the phase 3 spotlight study show that the study met its primary and key secondary end point of progression-free and overall survival.
Study Looks for Ways to Reduce Incidence of Tobacco-Associated Pancreatic CancerNovember 17th 2022
In an interview with Targeted Oncology, Nagaraj Nagathihalli, PhD, further explained the basis behind his study examining tobacco-associated pancreatic cancer and his plans to improve overall survival in this patient population.
Escalating Radiation Dose Shows Promise in Patients With Locally Advanced Pancreatic CancerNovember 17th 2022
In an interview with Targeted Oncology, Michael Chuong, MD, discussed how 5 fractions of ablative radiation therapy compare with 15-25 fractions for the treatment of locally advanced pancreatic cancer.
Phase 3 FRUTIGA Study of Fruquintinib Elicits Positive Results in Gastric/GEJ CancersNovember 16th 2022
Fruquintinib plus paclitaxel demonstrated improvements in progression-free survival, objective response rate, disease control rate, and more, in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
GOBLET Trial’s Pancreatic Cohort Displays High Efficacy With Pelareorep/AtezolizumabNovember 8th 2022
Treatment with pelareorep plus atezolizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma led to an overall response rate nearly triple than the average which were previously reported in historical control trials.
Health Derailed in Houston After Authorities Confirm Liver Cancer ClusterOctober 31st 2022
Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.
DeFianCe Study of DKN-01/Bevacizumab/Chemo Enrolls First Patient With Colorectal CancerOctober 19th 2022
The phase 2 DeFianCe study will evaluate the safety and efficacy of DKN-01 combined with bevacizumab and chemotherapy in patients with colorectal cancer vs becazixumab and chemotherapy alone.
DisTinGuish Trial Starts Enrollment of Patients with Gastric/GEJ CancersOctober 13th 2022
The first of 160 patients with gastric or gastroesophageal junction cancer has been recruited for the phase 2 DisTinGuish study. Thirty-two study locations are actively recruiting more patients.
Divergent Resistant Mechanisms Found With Upfront anti-EGFR Therapy in mCRCOctober 5th 2022
Analysis from the phase 3 CALGB/SWOG-80405 trial reveals that acquired genomic alterations in patients treated with cetuximab in combination with chemotherapy in the first-line were not common.